NCT07491419 The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST)
| NCT ID | NCT07491419 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituto Clinico Humanitas |
| Condition | Bloodstream Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-11-19 |
| Primary Completion | 2027-11-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2025-11-19 with a primary completion date of 2027-11-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The ACT-FAST study aims to compare commercially available Rapid Antimicrobial Susceptibility Testing (R-AST) tools with the current standard of care for patients with Bloodstream Infections (BSI). The primary objective is to evaluate whether "early targeted" antibiotic prescriptions, guided by these rapid tests, can improve antimicrobial stewardship and patient clinical outcomes. To facilitate the evaluation of various diagnostic tools-including those currently on the market and those emerging in the near future-this study utilizes an adaptive clinical trial platform. This flexible design allows for the continuous assessment of different R-AST technologies within a single master protocol, ensuring that the most effective diagnostic strategies are identified efficiently.
Eligibility Criteria
Inclusion Criteria: * Patients admitted to emergency department or hospitalized for any cause in participating hospitals with clinically suspected BSI and positive blood culture. * At least 18 years of age. Exclusion Criteria: * Have previously taken part in this trial. * Concurrently participating in the active phase of a study considered incompatible. * Patient with severe or terminal disease with life expectancy shorter than 48 h. * Have an existing directive to withhold life-sustaining treatment, in relation to antibiotic use.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07491419 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bloodstream Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07491419 currently recruiting?
Yes, NCT07491419 is actively recruiting participants. Contact the research team at michele.bartoletti@hunimed.eu for enrollment information.
Where is the NCT07491419 trial being conducted?
This trial is being conducted at Rozzano, Italy.
Who is sponsoring the NCT07491419 clinical trial?
NCT07491419 is sponsored by Istituto Clinico Humanitas. The trial plans to enroll 400 participants.